Beg, Muhammad Shaalan <br/><br/>
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.  [electronic resource] 

 -  Journal of surgical oncology  Jul 2017 
 - 83-88 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1096-9098 
<br/><br/><label>Standard No.: </label>10.1002/jso.24624  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Albumins--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Clinical Trials, Phase I as Topic<br/>Deoxycytidine--analogs & derivatives<br/>Humans<br/>NAD(P)H Dehydrogenase (Quinone)--antagonists & inhibitors<br/>Naphthoquinones--pharmacology<br/>Paclitaxel--pharmacology<br/>Pancreatic Neoplasms--drug therapy<br/>Gemcitabine